Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.

@article{Shannon1995RecombinantHE,
  title={Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.},
  author={Kevin M. Shannon and Julian F Keith and William C. Mentzer and Richard A. Ehrenkranz and Mark S. Brown and John A Widness and Christine A. Gleason and Ellen M. Bifano and Dietra Delaplane Millard and Charles B. Davis},
  journal={Pediatrics},
  year={1995},
  volume={95 1},
  pages={1-8}
}
DESIGN AND METHODS We hypothesized that treatment with recombinant human erythropoietin (r-HuEPO) would stimulate erythropoiesis and would thereby reduce the need for erythrocyte transfusions in preterm infants. We treated 157 preterm infants born at 26.9 +/- 1.6 weeks of gestation who weighed 924 +/- 183 g at birth with either subcutaneous r-HuEPO (100 U/kg/d, 5 days per week) or placebo for 6 weeks in a randomized, double-blind, controlled clinical trial. All patients received oral iron and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

Anaemia of Prematurity

PharmacoEconomics • 2012
View 9 Excerpts
Highly Influenced

Nutrient requirements for preterm infant formulas.

The Journal of nutrition • 2002
View 17 Excerpts
Highly Influenced

Treatment with erythropoietin in neonatology

MIKSIĆ MIRJANA, DUKIĆ VUKOVIĆ TANJA, P. Robert, TREIBER MILENA
2016
View 1 Excerpt

Similar Papers

Loading similar papers…